No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CRBU240719P2500
- 0.20
- +0.03+17.65%
15min DelayClose Jul 19 15:58 ET
0.25High0.17Low
0.20Open0.17Pre Close22 Volume197 Open Interest2.50Strike Price462.00Turnover0.00%IV-0.22%PremiumJul 19, 2024Expiry Date0.21Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma11.48Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Small-Cap Stocks Are Having a Moment. Check Out the 10 Biggest Winners.
Chatter about the timing of the Federal Reserve's first interest-rate cuts has shifted all the market hype from Goliath to David.
Strategic Focus and Financial Runway Extension Bolster Caribou Biosciences' Buy Rating
Caribou Cuts 12% of Workforce, Extends Cash Runway Into 2H 2026
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright analyst Robert Burns maintains $Caribou Biosciences(CRBU.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 28.2
Will Caribou Biosciences (NASDAQ:CRBU) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew
Express News | HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Comments
$Caribou Biosciences(CRBU.US$
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
1
$Caribou Biosciences(CRBU.US$ Got a inverted hammer on the daily! Its wick actually broke above the downtrend continuation wedge! Its Really OS RSI 7 = 14.58! RSI 14 = 24.96! MACD Looks as if its fixing to GC? So lets just see how this turns out? Just thinking outloud![]()
3
$Caribou Biosciences(CRBU.US$ Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
2
Caribou Biosciences' high P/S ratio, despite expected revenue slump and industry's predicted 250% growth, may worry investors. A potential disappointment awaits if the P/S aligns with the negative growth outlook.
Caribou Biosciences' revenue growth is promising but rising cash burn rate could concern investors. Raising more capital may result in shareholder dilution, making the situation risky.
Read more